About the Authors

Kari Hemminki

Roles Conceptualization, Formal analysis, Project administration

K.Hemminki@dkfz.de

Affiliations Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Asta Försti

Roles Investigation, Validation

Affiliations Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany, Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

Akseli Hemminki

Roles Investigation, Validation

Affiliations Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

Börje Ljungberg

Roles Investigation, Validation

Affiliation Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden

Otto Hemminki

Roles Conceptualization, Formal analysis, Supervision

Affiliations Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, Division of Urologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, Ontario, Canada

Competing Interests

The authors have read the journal’s policy and have the following competing interests: AH is shareholder in Targovax ASA. AH is also employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.